Tsang Wen, Gan Lu, Zhang Zhikun, Li Tong, Luo Yiqun, Zhong Liping, Huang Yong
National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China.
Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of China.
Onco Targets Ther. 2021 Oct 20;14:5085-5093. doi: 10.2147/OTT.S321658. eCollection 2021.
The occurrence, progression, invasion and metastasis of tumors depend on a tumor vascular network. Vascular disrupting agents (VDAs) are a new class of drugs targeting the tumor vasculature, by blocking the existing tumor blood vessels. However, there is no clear consensus on the clinical efficacy of tumor vascular disrupting therapy. In this study, we performed the first systematic review and meta-analysis of published clinical trials focused on tumor vascular disrupting therapies.
We searched PubMed, EMBASE, and the Cochrane Library to identify clinical trials that used VDAs to treat tumors. After literature screening and data extraction, according to inclusion and exclusion labels, meta-analysis was performed using RevMan5.3 software.
In this meta-analysis, we included 2659 patients from eight randomized controlled trials involving non-small-cell lung cancer, prostate, epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. Compared with the control arm, the experimental arm exhibited an effective improvement of 0.5-year and 1-year survival, as well as the 6-month progression-free survival rate. There was no significant difference between patients in the experimental compared to the control arm with respect to objective response and disease control rates, and 12-month progression-free survival.
Vascular disrupting therapy can effectively prolong the survival of cancer patients. However, for indicators of short-term efficacy, such as objective response rate and disease control rate, there is still a lack of high-quality, large-scale clinical trial data to confirm the effectiveness of VDAs.
肿瘤的发生、发展、侵袭和转移依赖于肿瘤血管网络。血管破坏剂（VDAs）是一类新型药物，通过阻断现有的肿瘤血管来靶向肿瘤脉管系统。然而，关于肿瘤血管破坏疗法的临床疗效尚无明确共识。在本研究中，我们对已发表的聚焦于肿瘤血管破坏疗法的临床试验进行了首次系统评价和荟萃分析。
我们检索了PubMed、EMBASE和Cochrane图书馆，以识别使用血管破坏剂治疗肿瘤的临床试验。经过文献筛选和数据提取，根据纳入和排除标准，使用RevMan5.3软件进行荟萃分析。
在这项荟萃分析中，我们纳入了来自八项随机对照试验的2659例患者，这些试验涉及非小细胞肺癌、前列腺癌、上皮性卵巢癌、输卵管癌和原发性腹膜癌。与对照组相比，试验组在0.5年和1年生存率以及6个月无进展生存率方面有有效改善。试验组与对照组患者在客观缓解率和疾病控制率以及12个月无进展生存率方面无显著差异。
血管破坏疗法可有效延长癌症患者的生存期。然而，对于客观缓解率和疾病控制率等短期疗效指标，仍缺乏高质量、大规模的临床试验数据来证实血管破坏剂的有效性。
